An Efficacy and Safety Trial of Intravenous Zoledronic Acid Twice Yearly in Osteoporotic Children Treated With Glucocorticoids

Exclusion Criteria

• •History of primary bone disease (OI, Idiopathic Juvenile Osteoporosis, Rickets/Osteomalacia)
• •Any medical condition that might have interfered with the evaluation of lumbar spine BMD, such as severe scoliosis or spinal fusion. Patients with less than 3 evaluable vertebrae by Dual Energy X-ray Absorptiometry (DXA) evaluation in the region of interest lumbar 1 (L1) to lumbar 4 (L4),
• •Hypocalcemia and hypophosphatemia
• •Serum 25-hydroxy vitamin D concentrations of \<20 ng/mL or \<50 nmol/L
• •estimated glomerular filtration rate (GFR) \<60 mL/min/1.73 m2
• •serum creatinine increase between Visit 1 and Visit 2 \>0.5 mg/dL (44.2 μmol/L)
• •Uncontrolled symptoms of cardiac failure or arrhythmia
• •Any prior use of bisphosphonates, or high dose sodium fluoride